LONDON, UK / ACCESSWIRE / October 6, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for KemPharm, Inc. (NASDAQ: KMPH), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=KMPH. The clinical-stage specialty pharmaceutical Company announced on October 03, 2017, that it has signed a technology licensing and assignment agreement with Genco Sciences, LLC, a privately held Company that develops proprietary products for the treatment of ADHD and Tourette’s/Tics. For immediate access to our complimentary reports, including today’s coverage, register for free now at:
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on KMPH. Go directly to your stock of interest and access today’s free coverage at:
About Tourette’s syndrome and ADHD
Tourette’s syndrome is an inherited neuropsychiatric disorder. It starts from childhood itself and is mainly characterized by the presence of motor and phonic tics. The treatment objective for this condition is more towards managing symptoms to achieve optimum functioning rather than eliminating symptoms. In fact, not all people suffering from Tourette’s require treatment. As of now, there is neither a cure nor any universally effective medication for this condition.
In about 90% cases, Tourette’s syndrome exists in combination with another disorder. Of this, the most common co-occurring condition is attention deficit hyperactivity disorder, i.e. ADHD. Approximately 63% of those diagnosed with Tourette’s have ADHD. However, the cause of this association is uncertain.
Terms and Conditions of the Agreement
As per the terms of the agreement, KemPharm would be responsible for financing as well as managing all the product development. In return, it would retain the complete intellectual property rights as well as commercial ownership of any product developed as a result of this agreement.
On the other hand, Genco would be eligible to get certain milestone and royalty-based or value share payments for the products developed under the agreement.
However, no additional details about the agreement were disclosed.
Agreement for Creation of Prodrug Therapy
Under the agreement, KemPharm would work towards developing a unique prodrug for the treatment of pediatric Tourette’s syndrome when accompanied by ADHD. For this KemPharm would leverage Genco’s early research-stage proprietary Nano-particulate amphetamine technology. Genco received an Orphan Designation letter from the US Food and Drug Administration’s (FDA) Office of Orphan Products Development for its product candidate for pediatric Tourette’s syndrome in 2016.
Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, shared his views regarding the agreement announcement. He mentioned that the license and assignment agreement with Genco would provide KemPharm’s discovery and development team the opportunity to apply its prodrug expertise to a potential orphan-drug area of the ADHD market. A significant proportion of pediatric Tourette’s syndrome patients suffer from ADHD. They need additional treatment, coexisting with the treatment for Tourette’s. He further announced that KemPharm aims to discover and develop a prodrug-based therapy that can provide a suitable treatment for a rare pediatric disease while also successfully concluding the FDA’s regulatory approval process. This would allow the Company to seek a Priority Review voucher subsequently.
Agreement to Build on KemPharm’s Proprietary LATTM Platform
KemPharm utilizes its proprietary LATTM (Ligand Activated Therapy) platform technology to create improved prodrug versions of FDA-approved drugs in the requisite areas of pain, ADHD and other central nervous system disorders. Moreover, the LAT platform exclusively provides an opportunity to receive a voucher under the current guidelines. This is another instance wherein prodrugs can be used to create value. Mickle believes that this agreement with Genco would build on the LAT platform and possibly add meaningful assets to KemPharm’s development pipeline in ADHD.
A Step Towards Treating Tourette’s syndrome
Subhash Desai, Ph.D., Chief Executive Officer at Genco, also expressed his positive remarks about the agreement. He stated that KemPharm’s success at creating exceptional prodrug product candidates in numerous treatment areas helps Genco realize the actual potential of a prodrug to be successful as the basis for treating this rare pediatric disease. He believes that by treating the underlying ADHD, they can also make way for treating tics and Tourette’s syndrome. This implies an effective therapy for the unmet needs of those affected by this challenging neurologic disorder.
Last Close Stock Review
On Thursday, October 05, 2017, the stock closed the trading session at $4.10, climbing 3.80% from its previous closing price of $3.95. A total volume of 35.90 thousand shares have exchanged hands. KemPharm’s stock price rallied 24.24% in the last one month and 24.24% in the past three months. Furthermore, since the start of the year, shares of the Company have soared 38.98%. The stock currently has a market cap of $60.93 million.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily
Information contained on this page is provided by an independent third-party content provider. Frankly and this Station make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact firstname.lastname@example.org